< Terug naar vorige pagina
Onderzoeker
Evelien Moorkens
- Disciplines:Ontdekking en evaluatie van biomarkers, Ontdekking en evaluatie van geneesmiddelen, Medicinale producten, Farmaceutica, Farmacognosie en fytochemie, Farmacologie, Farmacotherapie, Toxicologie en toxinologie, Andere farmaceutische wetenschappen
Affiliaties
- Klinische Farmacologie en Farmacotherapie (Afdeling)
Lid
Vanaf17 sep 2015 → 30 sep 2021
Projecten
1 - 1 of 1
- Een veelzijdige kijk op markttoegang van biosimilarsVanaf17 sep 2015 → 18 aug 2020Financiering: BOF - Nieuwe Onderzoeksinitiatieven
Publicaties
1 - 10 van 20
- The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures(2021)
Auteurs: Evelien Moorkens, Isabelle Huys, Arnold Vulto
Pagina's: 1 - 17 - A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study(2021)
Auteurs: Evelien Moorkens, Arnold Vulto, Steven Simoens, Isabelle Huys
- Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany(2020)
Auteurs: Evelien Moorkens, Arnold Vulto, Isabelle Huys, Steven Simoens
Pagina's: 1 - 20 - Biosimilars in Oncology – Part II: Considerations about the clinical use of oncology biosimilars(2020)
Auteurs: Liese Barbier, Evelien Moorkens, Yannick Vandenplas, Arnold Vulto
Pagina's: 286 - 292 - Biosimilars in oncology - Part I: The principles of biosimilars(2020)
Auteurs: Evelien Moorkens, Yannick Vandenplas, Liese Barbier, Arnold Vulto
Pagina's: 280 - 285 - A multifaceted view on market access of biosimilars(2020)
Auteurs: Evelien Moorkens, Isabelle Huys, Paul Declerck, Arnold Vulto
- Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?(2020)
Auteurs: Evelien Moorkens, Steven Simoens
Pagina's: 1 - 12 - Biosimilars in Belgium: a proposal for a more competitive market(2020)
Auteurs: Evelien Moorkens, Arnold Vulto, Isabelle Huys
Pagina's: 1 - 12 - An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?(2020)
Auteurs: Evelien Moorkens, Arnold Vulto, Isabelle Huys
Pagina's: 1 - 15 - Economic evaluation of biosimilars for reimbursement purposes – what, when, how?(2020)
Auteurs: Evelien Moorkens, Isabelle Huys, Arnold Vulto, Steven Simoens
Pagina's: 1 - 4